

SOD mRNA
SOD reverse transcription -
polymerase chain reaction(RT - PCR) enzyme linked
immunosorbent assay(ELISA)

가 ,

1996 7 1997 6

2

3 12

- 70

가 89

가 , ,

RNA

19

13

RT - PCR, 6 ELISA

RNA cDNA

50 200 μ l RNAZOL - B (Bioteck
Laboratory, Houston, Texas, USA) 1 2 ml

chloroform 100 μ l

DNA RNA

isopropanol 12,000 rpm 15

RNA 4 μ g

oligo - dT(16mer) 40 μ l

(reverse transcription, RT)

RNA 2 μ g, 5 mM MgCl₂, 50 mM KCl, 10 mM
Tris - HCl(pH 8.3), 1 mM dATP, 1 mM dTTP, 1 mM
dCTP, 1 mM dGTP, 1 U/ μ l RNase inhibitor(Perkin -
Elmer Corporation), 2.5 μ M oligo - dT ,
42 1 , 99 5 , 5 5

PCR

Cu/Zn SOD mRNA

superoxide dismutase sense primer

5' - TAGCGAGTTATGGCGACGAA - 3' antisense
primer 5' - ACGACTTCCAGCGTTTCCTG - 3'

, GAPDH sense primer

5' - CGTCTTCACCACCATGGAGA - 3' antise -
nse primer 5' - CGGCCATCAGCCACAGTTT - 3'

primer ()

RT - PCR 441 base pair

band SOD mRNA

PCR 5 μ l 10 $\times$ reaction buffer(15 mM
MgCl₂, 100 mM Tris - HCl, pH 8.3, 500 mM KCl)

10 mM dATP, dTTP, dCTP, dGTP, 20
mM sense antisense primer 1 μ l

mixture 2 μ l cDNA reaction mixture

2.5 unit Taq polymerase(Perkin - Elmer Corporation)

50 μ l

30 μ l

mineral oil DNA thermal cycler(Perkin -
Elmer Corp., Norwalk, CT, USA) PCR

PCR 94 1 , 60 1 , 72 1

GAPDH 25 cycle, SOD 34 cycle

1.5% agarose gel 1 $\times$ TAE(0.04 M Tris - acetate,
0.001 M EDTA) 0.3 μ g/ml ethidi -

um bromide , PCR 20 μ l 100

V(12 $\times$ 14 cm, 4.5 V/cm) 30

UV

ELISA

SOD

6 enzy -

me - linked immunosorbent assay(ELISA)

SOD . 0.1 M carbonate

buffer(pH 9.6) 1 : 8,000, 1 : 16,000, 1 : 32,000

1 : 65,000 50 μ l polystyrene

microtiter plate 4 overnight incubation

0.05% phosphate buffered saline(PBS) - Tween
buffer 5 . 5 monoclonal anti -

human SOD(mouse IgG1 isotype, Sigma Co, St. Louis,
MO, USA) 50 μ l coating polyst -

ylene microtiter plate 4 overnight in -

cubation 0.05% PBS - Tween buffer 5

. 5 peroxidase conjugated antimouse

IgG antibodies(Sigma Co, St. Louis, MO, USA)	50 μ l	SOD	ELISA
4	overnight incubation	0.05%	6
PBS - Tween buffer	5	5	0 -
phenylenediamine(Sigma Co, St. Louis, MO)	0.15 mg/ml	citric acid - phosphate buffer(pH 5.0)	2.5 M
492 nm			

가

SOD

PDH

RT - PCR

ELISA

SOD

GA

가

SOD

RT - PCR

13

4

12

GAPDH mRNA

3 (25%)

SOD mRNA

(Figs. 1 and 2).

(secretory otitis media)




Fig. 2. Detection of the expression for SOD mRNA by RT-PCR. Lanes : M ; marker, S ; serum, 1 to 13 ; Samples of OME




Fig. 2. Detection of the expression for SOD mRNA by RT-PCR. Lanes : M ; marker, S ; serum, 1 to 13 ; Samples of OME

가

3가

ELISA 6 4 SOD

가 SOD

ELISA

SOD mRNA 67% RT - PCR

23%

가

가

SOD

가

ELISA

가

SOD SOD mRNA가 SOD가

가 SOD

가 가

가

SOD RT - PCR ELISA RT - PCR

PCR GAPDH가 12 3

SOD mRNA

ELISA 6 4 SOD

가 SOD

SOD SOD mRNA가

가 가

가

Superoxide dismutase.

- 1) Blustone CD, Klein JO. *Otitis media, atelectasis, and Eustachian tube dysfunction*. In: Blustone CD, Stool SE, Scheetz MD. Editors. *Pediatric Otolaryngology*. 2nd ed. Philadelphia: WB Saunders; 1990. p.321-486.
- 2) Johnson MD, Fitz gerald JE, Leonard G, Burleson JA, Kreutzer DL. *Cytokine in experimental otitis media with effusion*. *Laryngoscope* 1994;104:191-6.
- 3) Punchard NA, Kelly FJ. *Introduction*. In: Punchard NA, Kelly FJ. editors. *Free radicals*. Oxford: Oxford University Press;1996. p.1-8.
- 4) Moslen MT. *Reactive oxygen species in normal physiology, cell injury and phagocytosis*. In: Armstrong D. editor. *Free radicals in diagnostic medicine: A systems approach to laboratory technology, clinical correlations, and antioxidant therapy*. New York: Plenum Press;1994. p.17-27.
- 5) Reaven PD. *Mechanisms of atherosclerosis: Role of LDL oxidation*. In: Armstrong D. editor. *Free radicals in diagnostic medicine: A systems approach to laboratory technology, clinical correlations, and antioxidant therapy*. New York: Plenum Press;1994. p.113-28.
- 6) Ferrari R. *Oxygen free radicals at myocardial level: Effect of ischemia and reperfusion*. In: Armstrong D. editor. *Free radicals in diagnostic medicine: A systems approach to laboratory technology, clinical correlations, and antioxidant therapy*. New York: Plenum Press;1994. p.99-112.
- 7) Ames BN, Shigenaga MK. *Oxidants are a major contributor to cancer and aging*. In: Halliwell B, Aruoma. editors. *DNA and free radicals*. New York: Ellis Horwood;1993. p.1-15.
- 8) Waz WR, Feld LG. *Reactive oxygen molecules in the kidney*. In: Armstrong D. editor. *Free radicals in diagnostic medicine: A systems approach to laboratory technology, clinical correlations, and antioxidant therapy*. New York: Plenum Press;1994. p.171-84.
- 9) Yagi K. *Lipid peroxides in hepatic, gastrointestinal and pancreatic disease*. In: Armstrong D. editor. *Free radicals in diagnostic medicine: A systems approach to laboratory technology, clinical correlations, and antioxidant therapy*. New York: Plenum Press;1994. p.165-70.

- 10) Halliwell B, Gutteridge JMC. *Protection against oxidants in biological systems: The superoxide theory of oxygen toxicity*. In Halliwell B, Gutteridge JMC editors. *Free radicals in biology and medicine*. 2nd ed. Oxford: Clarendon Press;1989. p.86-187.
- 11) Bernstaein JM. *The pathogenesis of otitis media with effusion: The role of virus and bacteria*. In: Mogi G. editor. *Recent advances in otitis media*. New York: Kugler Pub;1994. p.61-8.
- 12) Tos M. *Etiology of secretory otitis media: Tubal dysfunction or infection*. In: Mogi G. editor. *Recent advances in otitis media*. New York: Kugler Pub;1994. p.69-72.
- 13) Gates GA. *Acute otitis media and otitis media with effusion*. In: Cummings CW, Fredrickson JM, Harker LA, Krause CJ, Richardson MA, Schuller DA, editors. *Otolaryngology-Head & Neck Surgery*. 3rd ed. Vol 5. St. Louis: Mosby Year Book;1998. p.464-5.
- 14) Park JY, Moon IH, Jun BH. *Cytokine mRNA expression of otitis media with effusion in children*. *Korean J Otolaryngol* 1997;40:749-58.
- 15) Chang KH, Yeo SW, Suh BD. *Expression of tumor necrosis factor- α and Interleukin 10 in the middle ear effusion and histopathological changes of the middle ear mucosa in the rats with experimental otitis media with effusion*. *Korean J Otolaryngol* 1998;41:703-11.
- 16) Maxwell KS, Fitzgerald JE, Burleson JA, Leonard G, Carpenter R, Kreutzer DL. *Interleukin-8 expression in otitis media*. *Laryngoscope* 1994;104:989-95.
- 17) Juhn SK, Tolan CT, Garvis WJ, Cross DS, Giebink GS. *The levels of IL-1 β in human middle ear effusions*. *Acta Otolaryngol (stockh)* 1992;suppl. 493:37-42.
- 18) Parks RP, Huang CC, Haddad Jr J. *Evidence of oxygen radical injury in experimental otitis media*. *Laryngoscope* 1994;104:1389-92.
- 19) Kim DJ, Kim JG, Song DW, Ahn BH, Mun KC. *Oxygen free radical injury in human otitis media*. In: McCafferty, Coman W, Carroll R, editors. *Proceedings of XVI world congress of otorhinolaryngology head and neck surgery*. 1997 March 2-7;Sydney, Australia. Bologna, Italy: Monduzzi Editore;1997. p.889-92.
- 20) Parks RP, Huang CC, Haddad Jr J. *Superoxide dismutase in animal model of otitis media*. *Eur Arch Otorhinolaryngol* 1995;252:153-8.